Pimobendan in heart failure therapy - A silver bullet?

Journal of the American Animal Hospital Association

Volumn 42, Issue 2, 2006, Pages 90-93

  Gordon, Sonya G ^a   Miller, Matthew W ^a   Saunders, Ashley B ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; PIMOBENDAN; PLACEBO; SPIRONOLACTONE;

ARTICLE; BODY WEIGHT DISORDER; CHRONIC DISEASE; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; DOG DISEASE; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; HEART FAILURE; MORTALITY; NONHUMAN; QUALITY OF LIFE; VALVULAR HEART DISEASE;

CANIS FAMILIARIS;

EID: 33644987814     PISSN: 15473317     EISSN: 15473317     Source Type: Journal    
DOI: 10.5326/0420090     Document Type: Article

References (23)

1. Cove Study Group. Controlled clinical evaluation of enalapril in dogs with heart failure: results of the Cooperative Veterinary Enalapril Study Group. J Vet Intern Med 1995;9:243-252.
2. Ettinger SJ, Benitz AM, Ericsson GF, et al. Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. J Am Vet Med Assoc 1998;213:573-577.
3. The BENCH Study Group. The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial. J Vet Cardiol 1999;1:7-18.
4. van Meel JC, Diederen W. Hemodynamic profile of the cardiotonic agent pimobendan. Cardiovasc Pharmacol 1989;14(Suppl 2):S1-S6.
5. Sato N, Asai K, Okumura S, et al. Mechanisms of desensitization to a PDE inhibitor (milrinone) in conscious dogs with heart failure. Am J Phys 1999;276:H1699-H1705.
6. Verdouw PD, Hartog JM, Duncker DJ, et al. Cardiovascular profile of pimobendan, a benzimidazole-pyridazinone derivative with vasodilating and inotropic properties. Eur J Pharm 1986;126:21-30.
7. Ruegg JC. Effects of new inotropic agents on calcium sensitivity of contractile proteins. Circ 1986;73:78-84.
8. Mathew L, Katz S. Calcium sensitizing agents in heart failure. Drugs Aging 1998;12:191-204.
9. Sasayama S. Immune modulation of cardiac function: a new frontier. J Card Fail 1995;1:331-335.
10. Starling M. Evaluation and management of valvular heart disease. In: Proceed Valves in the Heart of the Big Apple II, New York, 2002, movie presentation.
11. Iwasaki A, Matsumori A, Yamada T, et al. Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis. J Am Coll Cardiol 1999;33:1400-1407.
12. Carabello B. Clinical assessment of systolic dysfunction. J Am Coll Cardiol 1994;3:25-29.
13. Urabe Y, Mann DL, Kent RL, et al. Cellular and ventricular contractile dysfunction in experimental canine initial regurgitation. Circ Res 1992;70:131-147.
14. Carabello B, Nolan SP, McGuire LB. Assessment of preoperative left ventricular function in patients with mitral regurgitation: value of the end-systolic wall stress-end-systolic volume ratio. Circulation 1981;64:1212-1217.
15. Carabello B. Mitral valve regurgitation. Curr Prob Cardiol 1998;23:202-241.
16. Fitton A, Brogden RN. Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure. Drugs Aging 1994;4:417-441.
17. Durand JB, Bachinski LL, Bieling LC, et al. Localization of a gene responsible for familial dilated cardiomyopathy to chromosome 1q32. Circulation 1995;92:3387-3389.
18. O'Grady MR, Minors SL, O'Sullivan L, et al. Evaluation of the efficacy of pimobendan to reduce mortality and morbidity in Doberman pinschers with congestive heart failure due to dilated cardiomyopathy (abstract). J Vet Intern Med 2003;17:440.
19. Lombard CW. Clinical experience with pimobendan. In: Proceed Vet Cardio Soc, Brit Small Anim Vet Assoc, Birmingham, 2000.
20. Fuentes VL, Corcoran B, French A, et al. A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy. J Vet Intern Med 2002;16:255-261.
21. O'Grady MR, Minors SL, O'Sullivan L, et al. Evaluation of the efficacy of pimobendan to reduce mortality and morbidity in dogs with congestive heart failure due to chronic mitral valve insufficiency (abstract). J Vet Intern Med 2003;17:410.
22. Smith PJ, French AT, Van Israel N, et al. Efficacy and safety of pimobendan in canine heart failure caused by myxomatous mitral valve disease. J Small Anim Pract 2005;46:121-130.
23. Haggstrom J, Hamlin R, Hansson K, et al. Heart rate variability in relation to severity of mitral regurgitation in Cavalier King Charles spaniels. J Small Anim Pract 1996;37:69-75.